Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Phase 2 Completed 35 enrolled NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).

Timeline

Start: 2014-11
Primary completion: 2015-06
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alprostadil	Unknown	300 ug	Topical
Subject	Alprostadil	Unknown	1000 ug	Topical
Subject	Alprostadil	Unknown	3000 ug	Topical

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Summary

Timeline

Drugs

Indications